arrow
U

Urban M. Fietzek

LMU Munich
H指数:29
被引数:2,822

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial

灵活剂量塔瓦帕多龙治疗帕金森病的安全性、耐受性和有效性(TEMPO-2):一项3期、随机、安慰剂对照、双盲试验

2026-07-150
PRE
A Biomarker-Based Classification of Corticobasal Syndrome

基于生物标志物的皮质基底综合征分类

2025-10-060
OAAI
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson's disease

一种定量 Lewy-fold 特异性 α-突触核蛋白种子扩增试验,作为帕金森病的进展标志物

2025-02-200
OA
Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies

结合脑脊液和PI 2620的tau-PET进行基于生物标志物的阿尔茨海默氏病和4r-tau病变分层

2024-09-121
OA
Subcortical tau is linked to hypoperfusion in connected cortical regions in 4-repeat tauopathies

皮质下tau与4重复tau病变中连接的皮质区域的灌注不足有关

BRAIN
IF11.7
2024-06-063
PRE
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies
2024-02-171
OAAI
[18F]F-DED PET imaging of reactive astrogliosis in neurodegenerative diseases: preclinical proof of concept and first-in-human data
2023-03-1110
OAAI
Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal

4重复tau病变的症状学与 [18F]-PI-2620 tau-PET信号的数据驱动拓扑有关

2023-01-016
OAAI
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
2022-09-1415
OAAI
18F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
2022-04-1419
OA